Literature DB >> 25755712

Sequential treatment with betulinic acid followed by 5-fluorouracil shows synergistic cytotoxic activity in ovarian cancer cells.

Ying-Jian Wang1, Jun-Bao Liu1, Yu-Chang Dou2.   

Abstract

Betulinic acid selectively inhibits the growth of ovarian carcinoma cell lines without affecting the normal cells. In the present study, the effect of 5-fluorouracil (5-FU) and betulinic acid (BA) combination on ovarian carcinoma cells was studied. The results demonstrated that ovarian carcinoma cells on concurrent or 5-FU followed by BA treatment show increased Sub-G1 cell population, increased rate of cell apoptosis and morphological changes in mitochondrial membrane. In OVCAR 432 cells treatment with sequential combination of 5-FU and BA increased the Sub-G1 cell population to 51.3% and growth inhibition rate of > 72%. However, exposure to BA before 5-FU treatment caused a decrease in rate of inhibition to < 35%. Treatment with combination of 5 μM of 5-FU and 1 μM of BA for 48 h, led to an induction of apoptosis in 79.7% and induced morphological changes in OVCAR 432 cells. The Western blot results showed high concentration of cytochrome c in the cell cytosol after 24 h of 5-FU and BA combination treatment. Treatment of BA-responsive RMS-13 cells with 5-FU and BA combination resulted in inhibition of GLI1, GLI2, PTCH1, and IGF2 genes. In addition, we found a significant reduction in hedgehog activity of RMS-13 cells after 5-FU and BA combination treatment by means of a hedgehog-responsive reporter assay. Therefore, 5-FU and BA combination can be a promising regimen for the treatment of ovarian carcinoma.

Entities:  

Keywords:  Ovarian carcinoma; apoptosis; hedgehog; inhibition; morphological changes

Mesh:

Substances:

Year:  2015        PMID: 25755712      PMCID: PMC4348889     

Source DB:  PubMed          Journal:  Int J Clin Exp Pathol        ISSN: 1936-2625


  27 in total

Review 1.  Cancer of the ovary.

Authors:  Stephen A Cannistra
Journal:  N Engl J Med       Date:  2004-12-09       Impact factor: 91.245

2.  A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H]thymidine incorporation assay.

Authors:  S A Ahmed; R M Gogal; J E Walsh
Journal:  J Immunol Methods       Date:  1994-04-15       Impact factor: 2.303

3.  Betulinic acid induces apoptosis in human neuroblastoma cell lines.

Authors:  M L Schmidt; K L Kuzmanoff; L Ling-Indeck; J M Pezzuto
Journal:  Eur J Cancer       Date:  1997-10       Impact factor: 9.162

4.  Betulinic acid triggers CD95 (APO-1/Fas)- and p53-independent apoptosis via activation of caspases in neuroectodermal tumors.

Authors:  S Fulda; C Friesen; M Los; C Scaffidi; W Mier; M Benedict; G Nuñez; P H Krammer; M E Peter; K M Debatin
Journal:  Cancer Res       Date:  1997-11-01       Impact factor: 12.701

Review 5.  Pharmacological properties of the ubiquitous natural product betulin.

Authors:  Sami Alakurtti; Taru Mäkelä; Salme Koskimies; Jari Yli-Kauhaluoma
Journal:  Eur J Pharm Sci       Date:  2006-04-29       Impact factor: 4.384

Review 6.  Uracil-tegafur in gastric carcinoma: a comprehensive review.

Authors:  H Takiuchi; J A Ajani
Journal:  J Clin Oncol       Date:  1998-08       Impact factor: 44.544

7.  Oxaliplatin/5fluorouracil-based chemotherapy was active and well tolerated in heavily pretreated patients with ovarian carcinoma.

Authors:  Daniela D Rosa; Ahmad Awada; Max S Mano; Jean Selleslags; Fabienne Lebrun; Thierry Gil; Martine J Piccart; Véronique D'Hondt
Journal:  Arch Gynecol Obstet       Date:  2008-02-14       Impact factor: 2.344

8.  Cisplatin combination chemotherapy versus chlorambucil in advanced ovarian carcinoma: mature results of a randomized trial.

Authors:  C J Williams; G M Mead; F R Macbeth; J Thompson; J M Whitehouse; H MacDonald; V J Harvey; M L Slevin; T A Lister; J H Shepherd
Journal:  J Clin Oncol       Date:  1985-11       Impact factor: 44.544

9.  A prospective randomized trial comparing high-dose cisplatin with low-dose cisplatin and chlorambucil in advanced ovarian carcinoma.

Authors:  E Wiltshaw; B Evans; G Rustin; E Gilbey; J Baker; G Barker
Journal:  J Clin Oncol       Date:  1986-05       Impact factor: 44.544

Review 10.  The anthracyclines: will we ever find a better doxorubicin?

Authors:  R B Weiss
Journal:  Semin Oncol       Date:  1992-12       Impact factor: 4.929

View more
  5 in total

1.  Betulinic Acid Induces Apoptosis in Differentiated PC12 Cells Via ROS-Mediated Mitochondrial Pathway.

Authors:  Xi Wang; Xiaocheng Lu; Ronglan Zhu; Kaixin Zhang; Shuai Li; Zhongjun Chen; Lixin Li
Journal:  Neurochem Res       Date:  2017-01-25       Impact factor: 3.996

2.  Betulinic Acid Suppresses Ovarian Cancer Cell Proliferation through Induction of Apoptosis.

Authors:  Dahae Lee; Seoung Rak Lee; Ki Sung Kang; Yuri Ko; Changhyun Pang; Noriko Yamabe; Ki Hyun Kim
Journal:  Biomolecules       Date:  2019-07-03

Review 3.  Anti-Inflammatory and Anticancer Properties of Birch Bark-Derived Betulin: Recent Developments.

Authors:  Hardeep Singh Tuli; Katrin Sak; Dhruv Sanjay Gupta; Ginpreet Kaur; Diwakar Aggarwal; Nidarshana Chaturvedi Parashar; Renuka Choudhary; Mukerrem Betul Yerer; Jagjit Kaur; Manoj Kumar; Vivek Kumar Garg; Gautam Sethi
Journal:  Plants (Basel)       Date:  2021-12-03

4.  Additive Interactions between Betulinic Acid and Two Taxanes in In Vitro Tests against Four Human Malignant Melanoma Cell Lines.

Authors:  Paula Wróblewska-Łuczka; Justyna Cabaj; Weronika Bąk; Julia Bargieł; Aneta Grabarska; Agnieszka Góralczyk; Jarogniew J Łuszczki
Journal:  Int J Mol Sci       Date:  2022-08-25       Impact factor: 6.208

5.  Biodegradable and Bioactive Carriers Based on Poly(betulin disuccinate-co-sebacic Acid) for Rifampicin Delivery.

Authors:  Daria Niewolik; Barbara Bednarczyk-Cwynar; Piotr Ruszkowski; Alicja Kazek-Kęsik; Grzegorz Dzido; Katarzyna Jaszcz
Journal:  Pharmaceutics       Date:  2022-03-06       Impact factor: 6.321

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.